Gene Therapy for Chronic Granulomatous Disease in Korea
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of administration of
autologous hematopoietic stem cells transduced with MT-gp91 retroviral vector for patients
with X-linked chronic granulomatous disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Helixmith Co., Ltd. ViroMed Co., Ltd. dba VM BioPharma